Statera Biopharma, Inc.: directors' dealings · United States · SEC (Form 4)

About Statera Biopharma, Inc.

Statera Biopharma, Inc. is a United States biopharmaceutical company that has been quoted on the NASDAQ market under the ticker STAB. For French, Belgian, and Swiss investors, the stock should be viewed as a high-risk small-cap biotech name whose equity story has been shaped by financing needs, portfolio changes, and material corporate events rather than by a mature commercial business. The company is incorporated in Delaware and has historically been associated with Fort Collins, Colorado, United States, where it maintained its principal operating footprint for a long period. More recent public disclosures, however, suggest that parts of Statera’s historical asset base and development programs were transferred or sold to other healthcare and biotech entities, which significantly limits the clarity of its current operating perimeter. Historically, Statera positioned itself as a developer of immunomodulatory therapies and immune-restoration platforms. Its core scientific narrative focused on restoring immune homeostasis rather than addressing a single pathway or a single disease mechanism. That positioning supported a development pipeline built around its AIMS platform, along with candidates aimed at inflammatory, autoimmune, oncology, and infectious-disease applications. Among the better-known programs were STAT-201, which was aimed at Crohn’s disease, and earlier assets linked to Entolimod, a program designed for radiation countermeasure and immune-restoration applications. From a competitive standpoint, Statera operated in a highly crowded biotechnology landscape dominated by large pharmaceutical groups, clinical-stage biotech peers, and platform companies pursuing differentiated immunology approaches. Its competitive advantage was primarily conceptual and scientific, based on the breadth of its platform and the optionality of its pipeline, rather than on approved products or a scaled commercial franchise. That can create upside in a favorable development scenario, but it also leaves shareholders exposed to substantial clinical risk, regulatory uncertainty, funding pressure, and dilution risk. The company did not appear to have a large, stable revenue base; instead, it relied on development-stage assets and, historically, on research-oriented subsidiaries and collaborations. Geographically, the company’s activities were mainly centered in the United States, especially Colorado. Its investor and development communications also referenced partnerships and collaborations with U.S.-based research institutions and industry participants. Recent developments are especially important: Statera’s corporate footprint has shrunk materially, and public market developments, including NASDAQ-related actions, have been central to the investment case. In practical terms, STAB should be analyzed less as a conventional growth biopharma and more as a distressed or restructuring-sensitive biotech situation, where asset-level events and corporate actions can matter more than traditional operating metrics.